Hilvo, M., Witoslawska, A., Lääperi, M., Jylhä, A., Lyytikäinen, L. P., Päivä, H., . . . Laaksonen, R. (2026). Ceramide-phospholipid risk score associates with cardiovascular events and is lowered by atorvastatin, simvastatin, and anti-PCSK9 treatments. Journal of cardiovascular pharmacology, 88(2), . https://doi.org/10.1097/FJC.0000000000001817
Citazione stile Chigago Style (17a edizione)Hilvo, Mika, et al. "Ceramide-phospholipid Risk Score Associates with Cardiovascular Events and Is Lowered by Atorvastatin, Simvastatin, and Anti-PCSK9 Treatments." Journal of Cardiovascular Pharmacology 88, no. 2 (2026). https://doi.org/10.1097/FJC.0000000000001817.
Citatione MLA (9a ed.)Hilvo, Mika, et al. "Ceramide-phospholipid Risk Score Associates with Cardiovascular Events and Is Lowered by Atorvastatin, Simvastatin, and Anti-PCSK9 Treatments." Journal of Cardiovascular Pharmacology, vol. 88, no. 2, 2026, https://doi.org/10.1097/FJC.0000000000001817.